CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 22 clinical trials at NIH that match your search criteria

Cancer by type/disease: Solid Tumor (Adult)

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase II
Phase II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes NCI-09-C-0047	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes NCI-08-C-0121	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligometastases NCI-07-C-0230	Deborah Citrin 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
Phase I
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers NCI-09-C-0173	Richard Piekarz 301-496-1196	Robin Frye 301-402-5958 fryer@mail.nih.gov
A Phase I, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies NCI-09-C-0111	Susan Bates 301-402-1357	Debbie Draper 301-435-8525 draperde@mail.nih.gov
An Open-Label Phase I Study to Evaluate the Safety and Tolerability of a Vaccine Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing Carcinoma NCI-09-C-0101	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Targeted Phase I Trial of ZD6474 (Vandetanib; ZACTIMA^®) Plus the Proteasome Inhibitor Bortezomib (Velcade^®) in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) NCI-09-C-0089	Antonio Tito Fojo 301-402-1357	Maureen Edgerly 301-435-5604 edgerlym@mail.nih.gov
A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas NCI-09-C-0048	Shivaani Kummar 301-435-5402	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors NCI-09-C-0019	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I and Pharmacokinetic Single-Agent Study of Pazopanib in Adults With Advanced Malignancies and Varying Degrees of Liver Dysfunction NCI-09-C-0003	Shivaani Kummar 301-435-5402	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
A Phase I Combination Study of AZD2281 and Cisplatin Plus Gemcitabine in Adults With Solid Tumors NCI-08-C-0128	Giuseppe Giaccone 301-496-4916	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I Study of SNX-5422 Mesylate in Adults With Refractory Solid Tumor Malignancies and Lymphomas NCI-08-C-0091	Giuseppe Giaccone 301-496-4916	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb^TM (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas NCI-08-C-0030	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Study of Batracylin (NSC320846) in Subjects With Solid Tumors and Lymphomas NCI-07-C-0097	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Trial of Nelfinavir (Viracept^®) in Adults With Solid Tumors NCI-07-C-0047	Phillip A. Dennis 301-496-0929	Hyejeong Root 301-402-0998 roothy@mail.nih.gov
A Phase I Trial of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies NCI-06-C-0221	James Doroshow 301-496-4291	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1 Alpha NCI-05-C-0186	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
A Phase I Investigation of IL-12/Pulse IL-2 in Adults With Advanced Solid Tumors NCI-00-C-0121	John E. Janik 301-402-2913	Debbie Draper 301-435-8525 draperde@mail.nih.gov
Phase 0
A Phase 0 Trial of [111] Indium CHX-A" DTPA Trastuzumab Imaging in Cancer NCI-07-C-0101	Peter Choyke 301-451-4220	Yolanda McKinney 301-443-6913 ymckinney@mail.nih.gov
No Phase
A Natural History Study of Patients Receiving High Dose Rate Brachytherapy NCI-09-C-0100	Aradhana Kaushal 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies NCI-07-C-0111	Deborah Citrin 301-496-5457	Sharon L. Smith 301-496-5457 smiths@mail.nih.gov
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease NCI-97-C-0147	W. Marston Linehan 301-496-6353

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.